Influence of the spread and period of retention of Iotrolan in the subarachnoid space on the side effects rate in myelography.
Fifty patients underwent myelography with the newly developed CSF-isotonic, dimeric, non-ionic contrast medium Iotrolan. Repeat spinal and cranial computerised tomographic studies with measurement of the attenuation values were conducted to demonstrate the administered contrast medium in the spinal canal and intracranial subarachnoid space. The patients were examined neurologically, observed clinically and asked about concomitant symptoms. The period of retention and the spread of the contrast medium in the subarachnoid space was not found to have any influence on the side effects rate. In particular, no association was confirmed between intracranially demonstrable contrast medium and the occurrence of side effects.
D000328:Adult; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000009:adverse effects* / Q000379:methods; D013346:Subarachnoid Space / Q000000981:diagnostic imaging / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000378:metabolism*
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C033300:iotrolan